Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Description

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

Conditions

Malignancy

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Condition
Malignancy
Intervention / Treatment

-

Contacts and Locations

Anchorage

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States, 98508

Anchorage

Anchorage Radiation Therapy Center, Anchorage, Alaska, United States, 99504

Anchorage

Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States, 99508

Anchorage

Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States, 99508

Anchorage

Alaska Women's Cancer Care, Anchorage, Alaska, United States, 99508

Anchorage

Anchorage Oncology Centre, Anchorage, Alaska, United States, 99508

Anchorage

Katmai Oncology Group, Anchorage, Alaska, United States, 99508

Anchorage

Providence Alaska Medical Center, Anchorage, Alaska, United States, 99508

Fairbanks

Fairbanks Memorial Hospital, Fairbanks, Alaska, United States, 99701

Kingman

Kingman Regional Medical Center, Kingman, Arizona, United States, 86401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Received a regimen containing one or more immuno-oncology therapeutics
  • * Must have experienced one or more of the following:
  • * One or more serious (Grade 3-4) AEs that are likely immune-related
  • * One or more Grade 2 dermatologic or rheumatologic AEs that are likely immune-related
  • * Diagnosis of a rare infection, e.g., fungal or mycobacterial, after starting IO treatment
  • * Hyperprogression. Image submission for patients experiencing hyperprogression is required. For assistance in determining hyperprogression for purposes of eligibility, institutions may contact the study chair and submit images for central review
  • * Has not previously been registered to this study

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Alliance for Clinical Trials in Oncology,

David Kozono, MD, PhD, STUDY_CHAIR, Brigham and Women's Hospital

Study Record Dates

2025-10-01